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Environews Forum
Science deals exclusively with things as they are in themselves.
John Ruskin (1819–1900)
Harnessing the HGP
for Public Health
The enormous amount of genetic data from
the Human Genome Project (HGP) has
benefited researchers studying gene–envi-
ronment interactions, but also presents
challenges in experimental design, data
management, and the ethical, legal,
and social implications of gene–envi-
ronment research. These challenges
were the topic of the symposium “The
Human Genome Project and Public
Health: Gene–Environment Inter-
actions,” part of the 2004 annual
meeting of the American Association
for the Advancement of Science in
Seattle, Washington. 
Presenters discussed strategies to
help researchers decide where to con-
centrate their research dollars and ener-
gy among the more than 7.2 million
genetic variations and single-nucleotide
polymorphisms (SNPs) cataloged by
the HGP. One strategy is to focus on
genes that are linked by function in
pathways, said Deborah Nickerson, a
professor in the University of Wash-
ington (UW) Department of Gen-
ome Sciences. She discussed progress
on SNP discovery in gene pathways for
the Environmental Genome Project,
especially the development of new
algorithms to explore associations
between SNPs in human genes and
environmental exposures. One pro-
gram—Hotspotter, developed by UW
assistant statistics professor Matthew
Stephens—helps researchers explore
recombination in human genes over time, a
history that affects SNP associations in the
human genome. 
Focusing on genes involved in key cel-
lular processes such as DNA repair is crit-
ical, according to symposium co-organizer
David Eaton, director of the NIEHS–UW
Center for Ecogenetics and Environ-
mental Health. Every day, each cell in the
human body withstands 10,000–20,000
oxidative assaults to DNA, and the vast
majority are repaired. Increased under-
standing of how this DNA repair happens
and other critical biochemical pathways
can lead to better methods for disease pre-
vention and more effective drugs with
fewer side effects, said Eaton. 
Better understanding of gene–environ-
ment interactions can also lead to more
accurate dosing of existing medications.
This is especially crucial for powerful drugs
where the margin between effective and
toxic doses is narrow, said Kenneth
Thummel, associate dean for research and
new initiatives of the UW School of
Pharmacy. One example is warfarin, an anti-
coagulant used to prevent recurrent myocar-
dial infarction and other thromboembolic
events. Variations in a single gene (CYP2C9)
can cause some people to be five times as
sensitive to the drug and make them sus-
ceptible to overdosing, which can cause
severe internal bleeding. According to
Thummel, genetic testing could be cost-
effective if it could replace some of the
blood tests now used to monitor warfarin
dosing—especially if it reduces hospitaliza-
tions by determining which patients need
lower doses of the drug and closer monitor-
ing. Other recent research may lead to
improved dosing for the immunosuppres-
sants cyclosporine and tacrolimus, which
can cause kidney damage and failure. 
Susceptibility to heart disease has also
been linked to numerous genes, including
APOE. Steve Humphries, a professor of
cardiovascular genetics at University Col-
lege London Medical School, reported that
variants of APOE are well known to raise
or lower blood levels of low-density
lipoprotein (“bad”) cholesterol, but only
have a significant impact on an individual’s
risk of heart disease when the person
smokes. Smoking increases the risk of
heart disease of people with any of three
common  APOE variants, but the risk is
greatest (about threefold) among car-
riers of the ε4 variant, which is
found in about 25% of the popula-
tion. Humphries and colleagues are
working with a smoking cessation
clinic in London to determine
whether smokers will be motivated
to quit if they learn that they have a
high genetic risk of disease. 
One possible complication is that
information about APOE4 status
could lead to fatalism rather than a
determination to quit smoking, said
symposium co-organizer Wylie Burke,
chair of the UW Department of
Medical History and Ethics. The issue
is further complicated by the fact that
the  APOE4 polymorphism has also
been linked to a higher risk of Alz-
heimer disease. People may view death
by heart disease as a blessing compared
to contracting Alzheimer disease, for
which there is as yet no cure and no
clear-cut means of prevention. There-
fore, knowing one’s own APOE4
status could decrease, rather than
increase, a person’s motivation to quit
smoking. In addition, according to
Burke, focusing on genetic susceptibil-
ity to smoking-related disease may
draw attention from more important
environmental factors, such as advertising,
that encourage people of all genotypes to
begin smoking in the first place. 
Many other findings in gene–environ-
ment interactions raise similar ethical,
legal, and social issues about whether socie-
ty should focus on labeling individuals as
susceptible to a given disease or simply
reduce environmental exposures for every-
one. “We need to be very careful to create
the right environment in this era of rapidly
accumulating genetic information,” said
Burke. “An overemphasis on the effects of
genes relative to the effects of the environ-
ment can lead to oversimplification of the
problem and distract attention from need-
ed environmental change.” –Kris Freeman
TOXICOGENOMICS
Too much information? Knowledge of genetic susceptibility
to smoking-related disease could actually decrease a person’s
motivation to quit.Environmental Health Perspectives • VOLUME 112 | NUMBER 7 | May 2004 A 403
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The Bleeding Edge
of Technology
In any given proteomics experiment, a cell or
tissue can express hundreds or thousands of
proteins at a time. Unlike the static genome,
the proteome can change quickly, and key
responses to toxicants and disease may
involve small amounts of rare proteins. As an
added complication, gene–protein and pro-
tein–protein interactions often are not linear.
So what’s a researcher to do? At the seminar
“Proteomics and Systems Biology,” held at
the 2004 annual meeting of the American
Association for the Advancement of Science
in Seattle, Washington, presenters discussed
advances at the “bleeding edge” of proteom-
ics research and their use in the study of
complex biochemical interactions within
and among cells—advances that may help
overcome some of the challenges posed by
proteomics. 
Seminar presenters discussed techniques
to both measure protein signals and analyze
the enormous amounts of data that result
from such experiments. In most of the exper-
iments reported, new techniques
were tested on biological systems
that had already been partially
characterized, such as blood plas-
ma. This allowed researchers to val-
idate their systems with the bonus
of potentially adding to knowledge
about the biological systems in
question.
In one analysis of blood plasma
conducted at Pacific Northwest
National Laboratory (PNNL), sci-
entists claim to have identified
about 3,700 proteins (not count-
ing immunoglobulins) from hum-
an plasma, results that are an order of mag-
nitude greater than those described only 18
months ago, according to Richard Smith,
director of the NIH Proteomics Research
Resource Center at PNNL. The newly
detected proteins include many found at
very  low levels, some of which could be
used as biomarkers of toxic exposure or dis-
ease progression, said Smith.
The plasma analysis used high-sensitivi-
ty, high-throughput instrumentation and
techniques developed at PNNL, including
Fourier transform ion cyclotron resonance
(an advanced form of mass spectrometry).
The PNNL researchers also separated out
the most abundant proteins, allowing meas-
urements to focus on less abundant proteins
and increasing the number of proteins
found in their plasma samples from about
1,000 to about 3,700. In addition, using
electrospray ionization and low flow rates of
solutions into the mass spectrometer facili-
tated detection of proteins in amounts as
small as 10 zeptomoles, a level of sensitivity
that makes it possible to analyze many pro-
teins expressed by a single cell, said Smith.
Leroy Hood, president of the nonprofit
Institute for Systems Biology (ISB), too, dis-
cussed the potential for analyzing single cells.
Researchers at the ISB and the California
Institute of Technology are developing nano-
chips measuring 100 microns on a side that
will assess the behavior of individual cells
and gauge the concentrations of the mRNAs
and proteins from a single cell. The ISB
researchers have applied microfluidics—the
study of how fluids behave at the nano
level—to successfully conduct biological
assays on single cells. ISB and Caltech
researchers are now working on nanochips
that can analyze several cells simultaneously.
“We’ll be able to interrogate a T cell and then
an antigen-presenting cell separately. Then
we will let the cells interact and interrogate
their combined behaviors,” said Hood. 
Some presenters noted cautions about
the prospects for analysis of single, living
cells. Smith, for example, said that much
more progress is needed in
areas such as the construc-
tion of nanochips and
microfluidics in order to
make these methods of
measurement “truly useful
and not just a stunt.”
Presenter Matthias Mann, a professor of
biochemistry and molecular biology at the
University of Southern Denmark, empha-
sized the need to distinguish between at least
three states to track changes in protein
expression. He displayed preliminary data
from cells that were treated with a growth
factor and sampled at five points. Analysis
detected changes in levels of about 400 phos-
phoproteins over time. “The activation of
some proteins decayed faster, and some pro-
teins were activated later,” Mann said. 
Beyond the proteome is the metabo-
lome—the sugars, amino acids, and other
molecules that are created by or combine to
create proteins. Masaru Tomita and col-
leagues at Keio University and the bioven-
ture firm Human Metabolome Technologies
are combining capillary electrophoresis and
mass spectrometry to analyze the metabolites
from rice, Escherichia coli, and Bacillus sub-
tilis. For the purposes of these experiments,
the team defined metabolites as molecules
with a molecular weight of less than 1,000.
In one experiment, the team detected more
than 1,700 possible metabolites. The team is
now constructing a model of entire metabol-
ic pathways with several thousand reactions. 
It may never be possible to fully describe
the proteome of any species. Unlike the
genome, which Hood characterized as “dig-
ital” and so “ultimately knowable,” the pro-
teome is affected by a multitude of external
factors. In its absolute sense, according to
Mann, the proteome is “as unreachable as
the horizon.” –Kris Freeman
PROTEOMICS
Big picture, tiny molecules. A PNNL researcher performs an experiment on the Fourier trans-
form ion cyclotron resonance mass spectrometer, which is used to characterize proteins such as
those in blood plasma (inset).Diet and DNA
The emerging field of nutrigenomics explores
how nutrients in foods interact with genes
that contribute to chronic diseases. The goal
of nutrigenomics is to understand individual
nutrient genotypes to design dietary inter-
ventions that restore health or prevent dis-
ease, eventually improving the health of the
population at large as well as that of specific
subpopulations. The fledgling field is packed
with promise, and two new research initia-
tives aim to help deliver on that promise. 
A Center of Excellence for Nutritional
Genomics was established in 2003 at the
University of California (UC), Davis, to
coordinate nutrigenomics studies among
participating institutes. A five-year, $6.5 mil-
lion grant from the NIH National Center on
Minority Health and Health Disparities
funds the project. Genetics professor Ray-
mond Rodriguez directs the new center,
which unites 25 experts in nutrition, molec-
ular biology, bioinformatics, and related
fields from UC Davis, the Children’s Hosp-
ital Oakland Research Institute, the U.S.
Department of Agriculture Western Human
Nutrition Research Center, and the Ethnic
Health Institute at Alta Bates Summit Med-
ical Center. Center members will explore
how different foods interact with genes to
increase the risk of type 2 diabetes mellitus,
obesity, heart disease, and cancer.
Across the Atlantic, the European Nutri-
genomics Organisation (NuGO) was
launched in February 2004. This network of
22 scientists from 10 European countries
will receive ¤17.3 million from the Euro-
pean Union over six years to develop new
technologies, improve model systems, and
advance nutritional bioinformatics. “Partic-
ular attention will be given to studies of
human volunteers, and both biomarkers and
new methods will be developed and validat-
ed,” says Siân Astley, NuGO’s communica-
tions manager. 
“Nutritional genomics connects the
Human Genome Project to human health in
the most personal ways—through the foods
we eat several times a day,” says Rodriguez.
“A  better understanding of how diet and
genes interact will enable us to better manage
our own health and possibly prevent, miti-
gate, or delay the onset of chronic and age-
related diseases.” 
People react to certain nutrients differ-
ently, depending on their genetic makeup.
Lactose intolerance, a well-known example
of nutrigenomics, afflicts largely Asians and
Africans, and far fewer people of northern
European descent. That’s because a single
base pair change in DNA occurred in north-
ern Europe about 6,500–12,000 years ago,
which allowed people there to digest lac-
tose—in an environment with a short grow-
ing season, access to the additional nutritious
food source of milk was helpful for survival,
says Jim Kaput, a pioneer of nutrigenomics
and founder of the diagnostics company
NutraGenomics. 
Today’s nutrigenomics researchers hope
to find gene variants that explain why, for
instance, some people can lower their blood
pressure through dietary changes, while oth-
ers need drugs. Other variations might
explain why some people are more suscepti-
ble to gastrointestinal cancers, inflammatory
diseases, and osteoporosis.
Scientists are finding that biologically
active components of foods can alter gene
expression. For example, a deficiency of folic
acid may lead to breaks in DNA that mimic
radiation damage. Other nutrients are
involved in molecular processes related to
DNA structure, gene expression, and metab-
olism, which contribute to the development
of chronic illnesses. 
The nutrigenomics approach resembles
pharmacogenomics, which looks at the
relationship between single-nucleotide
polymorphisms in genes and patients’
responses to drugs to personalize medicine.
Although progress in pharmacogenomics
currently surpasses that in nutrigenomics,
the two are closely linked. “Without nutri-
genomics, pharmacogenomic data cannot
be interpreted correctly, because diet may
affect the expression of genes involved in
drug metabolism,” says Kaput. He propos-
es that pharmaceutical companies should
include nutrigenomics in the design of new
drugs because, he says, “what you eat affects
a drug’s efficacy.” –Carol Potera
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NUTRIGENOMICS
Lessons from lunch. The field of nutrigenomics is examining the nexus between diet and genetic susceptibility to disease.How Viruses
Sabotage Silencing
The discovery and description of RNA si-
lencing less than a decade ago has spawned
a flood of research, revolutionizing the
practice of functional genomics and leading
to intensive exploration of its potential
application to treat numerous diseases.
RNA silencing was first noticed in plants
when attempts to create transgenic plants
that overexpressed a natural gene often had
the opposite effect; later it was found to be
an evolutionarily conserved defense mecha-
nism against plant RNA viruses and other
molecular parasites. Viruses, in turn, have
evolved their own counterdefense mecha-
nisms: proteins that suppress RNA silenc-
ing, allowing the virus to maintain its inva-
sion of a plant. Until recently, the mecha-
nism behind this suppression of silencing
was a mystery, but researchers at the
NIEHS and the Agricultural Biotechnology
Center in Gödöllõ, Hungary, have begun to
unravel how some viruses neutralize silenc-
ing, shedding important new
light on a complex molecular
interaction.
In the 26 December 2003
issue of Cell, NIEHS investigator
Traci M. Tanaka Hall, postdoctoral
researcher Jeffrey Vargason, and
Hungarian colleagues József Burgyán and
György Szittly elucidate the nature of viral
counterdefense by solving the crystal
structure of a known silencing suppressor,
the tombusvirus Carnation Italian ringspot
virus (CIRV) p19 protein, in complex
with a 21-nucleotide small interfering
RNA (siRNA), the workhorse bit of
nucleic acid that drives the silencing
process. The structure of a similar p19
protein found in another tombusvirus was
published by Keqiong Ye, Lucy
Malinina, and Dinshaw Patel,
all of the Memorial Sloan-
Kettering Cancer Center, in the
18/25 December 2003 issue of
Nature. The slight differences in the
structures have allowed researchers to draw
further inferences about how a virus can
interfere with RNA silencing.
There are two classes of plant siRNAs.
The shorter ones, measuring 21–22 nucleo-
tides, are responsible for detecting and
destroying molecular invaders. The longer
ones, measuring 24–26 nucleotides, are sus-
pected to be more involved with regulating
retrotransposons and DNA methylation.
The structure of p19 reveals that the protein
selectively recognizes silencing siRNAs by
measuring their length. Tryptophan residues
(Trp39 and Trp42) on the protein act like
molecular calipers, forming a so-called
stacking interaction with the ends of the end
base pairs of the shorter siRNAs. By binding
to the silencing siRNAs, the protein in effect
sequesters them, rendering them incapable
of carrying out their silencing mission and
allowing the virus to run rampant within
the plant. 
The protein can also bind to the longer
siRNAs, but much more weakly. “Viruses
are smart,” says structural biologist Tanaka
Hall. “They don’t want to kill their hosts too
quickly. They want to have time to replicate.
So  it makes sense that the virus spares
processes that might be essential to the
plant’s survival and not directed
against virus invasion.” 
The team also stud-
ied the importance
of tryptophan
residues to p19’s silencing suppression
effects by introducing mutations into the
p19 coding sequence of the CIRV genome
to change one or both of the tryptophan
residues. A protein database search had
shown that both tryptophans were not
absolutely conserved in all identified viral
p19 sequences, although all sequences con-
served at least one of the tryptophans, with
the other residue usually capable of forming
a stacking interaction. Their findings sug-
gest that while the virus can at least partial-
ly succeed in suppressing silencing with two
residues capable of stacking, substituting
one with a glycine residue lacking a side
chain results in failure of the suppression
and recovery of the plant from infection.
p19 has emerged as an important
research tool in the quest to refine scientif-
ic understanding of how siRNAs and other
small RNAs, such as microRNAs, work in
planta, in vitro, and in vivo. Unlike silenc-
ing siRNAs themselves, which rely on
sequence specificity to accomplish their
effects, p19 appears to simply meas-
ure the siRNAs and neutralize
those designed for silencing. This
mechanistic revelation will enhance
the value of the protein as
researchers continue their efforts to
clarify the biological roles of small
RNAs in gene silencing and
other cellular regulatory and
developmental processes.
According to RNA silenc-
ing research pioneer Phillip
Zamore, an associate professor
in the Department of Bio-
chemistry and Molecular Phar-
macology at the University of
Massachusetts Medical School,
Tanaka Hall’s structure of the
p19 protein also provides great
insight into the RNA silencing
pathway itself. “All future
models of the RNA interfer-
ence pathway must incorporate
a step at which they are vulnera-
ble to siRNA sequestration by
p19,” he says. “This conclusion is
inescapable once one has seen the
structure.”
Tanaka Hall’s group plans to
continue to use p19 in its investi-
gations. “We’re particularly looking
at its role in being able to inhibit
microRNA-initiated processes, look-
ing biochemically at how p19 combines
with microRNAs,” she says. Structural
imaging of that relationship could aid in
explaining the still poorly understood
mechanisms by which microRNAs accom-
plish their cellular tasks. –Ernie Hood
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Potent punch. The CIRV
p19 protein (blue and green
ribbons) plus a 21-nucleotide
siRNA (beige balls) adds up to a
lethal combination that enables viruses to
counter a plant’s attempt at RNA silencing.A 406 VOLUME 112 | NUMBER 7 | May 2004 • Environmental Health Perspectives
Forum
T
o
p
 
t
o
 
b
o
t
t
o
m
:
S
i
n
c
l
a
i
r
 
S
t
a
m
m
e
r
s
/
W
H
O
 
T
D
R
;
 
I
S
C
;
 
S
i
n
c
l
a
i
r
 
S
t
a
m
m
e
r
s
/
W
H
O
 
T
D
R
;
 
A
.
W
.
 
T
a
y
l
o
r
-
R
o
b
i
n
s
o
n
/
W
H
O
T
D
R
International Sequencing Consortium txgnet
The sequencing of multiple species’ genomes
by the Human Genome Project, including those
of the human, the worm Caenorhabditis ele-
gans, and the fruit fly Drosophila melano-
gaster, has laid the foundation for the field of
comparative genomics. Experts believe this
field of study represents the next step in
genomic exploration, and that sequencing of
more organisms will be critical to answering
cross- and multispecies genomic questions. The
International Sequencing Consortium (ISC) was
established in 2002 to provide a worldwide
forum for genomic sequencing groups and
their funding agencies to share information,
coordinate research efforts, and address com-
mon issues raised by genomic sequencing, such as
data quality and release. The ISC has established
a free website at http://www.intlgenome.org/
where scientists and the public can get the latest
information on the status of sequencing projects
for the genomes of
animals, plants, and
other eukaryotic
organisms.
The ISC website
consists essentially
of a database of
sequencing proj-
ects. The database can be searched and sorted
by organism, sequencing group, or funding
agency. In addition, information is provided for
each organism on the region of the genome
being studied, strategies being used, the pur-
pose of the study, collaborating groups, and
the timetable for the project, if known. 
In most cases, links in the database connect
users directly to individual websites for the proj-
ect, sequencing group, or funding agency. For
example, the website lists a project for
sequencing the mosquito species Anopheles
gambiae, the principal vector of malaria. The
project was conducted by Genoscope (the na-
tional center for se-
quencing in France)
with funding by the
U.S. Agency for In-
ternational Devel-
opment, the World
Health Organization
Special Programme
for Research and Training in Tropical Diseases,
and the French Ministry of Research. Another link
on the ISC site connects to the completed pro-
ject’s website, where information is provided on
the scope and importance of this work. 
The ISC site also contains a listing of links to
other resources categorized under the head-
ings of microbial websites, genome browsers,
trace archives, and other genome-related sites
including other public databases where DNA
sequence data are deposited.
Members of the ISC include large-scale,
high-throughput sequencing centers and their
funding agencies, all of whom have agreed to
continue generating publicly available
sequence data for unrestricted use by the re-
search community. Most of the sequencing
projects included
in the ISC database
adhere to the poli-
cy of rapid release
of prepublication
data that has been
established by the
National Human
Genome Research Institute and The Wellcome
Trust for efforts  designated as “community
resource projects.” –Kimberly G. Thigpen